AU2018379426B2 - Selecting for developability of polypeptide drugs in eukaryotic cell display systems - Google Patents

Selecting for developability of polypeptide drugs in eukaryotic cell display systems Download PDF

Info

Publication number
AU2018379426B2
AU2018379426B2 AU2018379426A AU2018379426A AU2018379426B2 AU 2018379426 B2 AU2018379426 B2 AU 2018379426B2 AU 2018379426 A AU2018379426 A AU 2018379426A AU 2018379426 A AU2018379426 A AU 2018379426A AU 2018379426 B2 AU2018379426 B2 AU 2018379426B2
Authority
AU
Australia
Prior art keywords
cct
ctg
tcc
ccc
gtg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018379426A
Other languages
English (en)
Other versions
AU2018379426A1 (en
Inventor
Michael Richard Dyson
John Mccafferty
Kothai PARTHIBAN
Rajika PERERA
Johanna Liinamaria SYRJANEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iontas Ltd
Original Assignee
Iontas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iontas Ltd filed Critical Iontas Ltd
Publication of AU2018379426A1 publication Critical patent/AU2018379426A1/en
Application granted granted Critical
Publication of AU2018379426B2 publication Critical patent/AU2018379426B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2018379426A 2017-12-06 2018-12-05 Selecting for developability of polypeptide drugs in eukaryotic cell display systems Active AU2018379426B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1720351.4 2017-12-06
GBGB1720351.4A GB201720351D0 (en) 2017-12-06 2017-12-06 Selecting for developability in drug discovery
PCT/EP2018/083698 WO2019110691A1 (en) 2017-12-06 2018-12-05 Selecting for developability of polypeptide drugs in eukaryotic cell display systems

Publications (2)

Publication Number Publication Date
AU2018379426A1 AU2018379426A1 (en) 2020-06-18
AU2018379426B2 true AU2018379426B2 (en) 2025-05-22

Family

ID=60950392

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018379426A Active AU2018379426B2 (en) 2017-12-06 2018-12-05 Selecting for developability of polypeptide drugs in eukaryotic cell display systems

Country Status (8)

Country Link
US (1) US11499150B2 (enExample)
EP (1) EP3720959A1 (enExample)
JP (2) JP7744746B2 (enExample)
CN (1) CN111448314B (enExample)
AU (1) AU2018379426B2 (enExample)
CA (1) CA3083571A1 (enExample)
GB (1) GB201720351D0 (enExample)
WO (1) WO2019110691A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3786292A1 (en) * 2016-01-08 2021-03-03 Maxion Therapeutics Limited Binding members with altered diversity scaffold domains
GB201720162D0 (en) * 2017-12-04 2018-01-17 Univ Oxford Innovation Ltd Method
WO2021018114A1 (zh) * 2019-07-30 2021-02-04 中山康方生物医药有限公司 抗人p40蛋白域抗体及其用途
GB202014851D0 (en) 2020-09-21 2020-11-04 Iontas Ltd SARS-COV-2 antibodies
CN118525099A (zh) 2021-08-25 2024-08-20 艾恩塔斯有限公司 真核细胞中表达的蛋白质变体文库的制备
WO2023039528A1 (en) * 2021-09-10 2023-03-16 The Board Of Trustees Of The Leland Stanford Junior University Nanobody-mediated control of gene expression and epigenetic memory
US12091694B2 (en) 2022-11-18 2024-09-17 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
EP4646476A1 (en) 2023-01-06 2025-11-12 Seismic Therapeutic, Inc. Protease variants and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300065B1 (en) * 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US20050048578A1 (en) * 2003-06-26 2005-03-03 Epitomics, Inc. Methods of screening for monoclonal antibodies with desirable activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485943B2 (en) * 1995-01-17 2002-11-26 The University Of Chicago Method for altering antibody light chain interactions
JP2010213725A (ja) * 1998-01-20 2010-09-30 Univ Illinois タンパク質の酵母細胞表面ディスプレイおよびその使用
PT2702160T (pt) 2011-04-27 2020-07-30 Amyris Inc Métodos para modificação genómica
EP2794662A1 (en) 2011-12-22 2014-10-29 F.Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300065B1 (en) * 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US20050048578A1 (en) * 2003-06-26 2005-03-03 Epitomics, Inc. Methods of screening for monoclonal antibodies with desirable activity

Also Published As

Publication number Publication date
US20210163923A1 (en) 2021-06-03
AU2018379426A1 (en) 2020-06-18
US11499150B2 (en) 2022-11-15
GB201720351D0 (en) 2018-01-17
CN111448314A (zh) 2020-07-24
EP3720959A1 (en) 2020-10-14
JP7744746B2 (ja) 2025-09-26
WO2019110691A1 (en) 2019-06-13
CA3083571A1 (en) 2019-06-13
JP2021509010A (ja) 2021-03-18
JP2024009895A (ja) 2024-01-23
CN111448314B (zh) 2024-10-18

Similar Documents

Publication Publication Date Title
AU2018379426B2 (en) Selecting for developability of polypeptide drugs in eukaryotic cell display systems
JP6738397B2 (ja) 真核細胞において発現されるタンパク質変異体のライブラリーの調製、及び結合性分子の選択に向けた使用
JP2021524249A (ja) 抗ｃｄ３抗体及びその使用
IL293385A (en) New anti–pd–1 antibodies
EP3625250B1 (en) Single chain vh and heavy chain antibodies
AU2021395027A9 (en) Heavy chain-only antibodies
Su et al. Mimicking the germinal center reaction in hybridoma cells to isolate temperature-selective anti-PEG antibodies
WO2024251820A1 (en) Preparation of libraries of bispecific binders expressed in eukaryotic cells
KR20220087488A (ko) Pd-l1 결합 분자
Huhtinen ADVANCING ANTIBODY ENGINEERING
HK40031558B (zh) 用於新颖抗原结合模块的特异性测试的通用报告细胞测定法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)